ZUPREME: Petrelintide Phase 2 trial (NCT06662539)
A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 493
- actual
- Start
- 9 Dec 2024 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Sponsor
- Zealand Pharma
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Petrelintide Dose 1 | Experimental | Drug: Petrelintide | Participants will self-inject petrelintide dose 1 subcutaneously once a week. |
| Petrelintide Dose 2 | Experimental | Drug: Petrelintide | Participants will self-inject petrelintide dose 2 subcutaneously once a week. |
| Petrelintide Dose 3 | Experimental | Drug: Petrelintide | Participants will self-inject petrelintide dose 3 subcutaneously once a week. |
| Petrelintide Dose 4 | Experimental | Drug: Petrelintide | Participants will self-inject petrelintide dose 4 subcutaneously once a week. |
| Petrelintide Dose 5 | Experimental | Drug: Petrelintide | Participants will self-inject petrelintide dose 5 subcutaneously once a week. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will self-inject matching placebo to petrelintide subcutaneously once a week. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent change from baseline in body weight to Week 28 | From Baseline (Day 1) to Week 28 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants achieving ≥5% Body Weight Loss at Weeks 28 and 42 | From Baseline (Day 1) to Weeks 28 and 42 |
| Percentage of Participants achieving ≥10% Body Weight Loss at Weeks 28 and 42 | From Baseline (Day 1) to Weeks 28 and 42 |
| Change from baseline in body weight to Weeks 28 and 42 | From Baseline (Day 1) to Weeks 28 and 42 |
| Change from baseline in waist circumference to Weeks 28 and 42 | From Baseline (Day 1) to Weeks 28 and 42 |
| Percent change from baseline in body weight to Week 42 | From Baseline (Day 1) to Week 42 |
| Change from baseline in hemoglobin A1c (HbA1c) to Week 42 | From Baseline (Day 1) to Week 42 |
| Change from baseline in fasting glucose to Week 42 | From Baseline (Day 1) to Week 42 |
| Change from baseline in high-sensitivity C-reactive protein (hsCRP) to Week 42 | From Baseline (Day 1) to Week 42 |
| Change from baseline in fasting lipids to Week 42 | From Baseline (Day 1) to Week 42 |
| Number of treatment emergent adverse events (TEAEs) | From Baseline (Day 1) to Week 51 |
| Occurrences of anti-drug antibodies (ADAs) to petrelintide | From Baseline (Day 1) to Week 51 |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.